Cart
sales@molnova.com
Nufenoxole
CAS No. 57726-65-5
Nufenoxole( —— )
Catalog No. M36206 CAS No. 57726-65-5
Nufenoxole is an orally active and antidiarrhoeal compound that inhibits fluid secretion in the human jejunum.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 276 | In Stock |
|
| 10MG | 394 | In Stock |
|
| 25MG | 616 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNufenoxole
-
NoteResearch use only, not for human use.
-
Brief DescriptionNufenoxole is an orally active and antidiarrhoeal compound that inhibits fluid secretion in the human jejunum.
-
DescriptionNufenoxole is an orally active and antidiarrhoeal compound that inhibits fluid secretion in the human jejunum.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number57726-65-5
-
Formula Weight387.52
-
Molecular FormulaC25H29N3O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN=1N=C(OC1C)C(C=2C=CC=CC2)(C=3C=CC=CC3)CCN4CC5CCC4CC5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
APOL1-IN-1
APOL1-IN-1 is a potent inhibitor of apolipoprotein L1 (APOL1) that can be used to study the pathogenesis of focal segmental glomerulosclerosis (FSGS) and nondiabetic kidney disease (NDKD), facilitating research into these diseases.
-
MM-102 TFA
MM-102 TFA is a potent WDR5/MLL interaction inhibitor, achieves IC50 = 2.4 nM.?MM-102 compound prevents the interaction between mixed lineage leukemia 1 (MLL1) and WD Trp-Asp repeat domain 5 (WDR5) and results in the inhibition of MLL1 H3K4 histone methyltransferase (HMT) activity.
-
Crenulatin
Crenulatin has dual- direction effects on apoptosis of cerebral microvascular endothelial cells, inhibitive effect in 25 mg/L and stimulative effect in 100 mg/L group, respectively; the mechanism is related to the alterations of Fas/Bcl-2 expression and caspase-3 activity.
